Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 6/20 | 0.47 |
| ▸ | GRM5 | P41594 | 6/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11033370 | 1.00 | NPSR1 (0.47) | NPSR1FPR2GRM5CES2PTGS1 | |
| SCHEMBL11028187 | 0.86 | GRM5 (0.57) | FPR2GRM5CES2MAPTMEN1 | |
| SCHEMBL11032019 | 0.86 | GRM5 (0.57) | FPR2GRM5CES2MAPTMEN1 | |
| SCHEMBL11028750 | 0.86 | GRM5 (0.57) | FPR2GRM5CES2MAPTMEN1 | |
| SCHEMBL11030974 | 0.84 | FPR2 (0.66) | FPR2GRM5LMNAKCNK3MEN1 | |
| SCHEMBL11033371 | 0.84 | NPSR1 (0.49) | NPSR1FPR2GRM5CES2PTGS1 | |
| SCHEMBL11028967 | 0.84 | GRM5 (0.64) | FPR2GRM5 | |
| SCHEMBL11028866 | 0.84 | GRM5 (0.64) | FPR2GRM5 | |
| SCHEMBL11032468 | 0.84 | GRM5 (0.64) | FPR2GRM5 | |
| SCHEMBL11031568 | 0.84 | FPR2 (0.66) | FPR2GRM5LMNAKCNK3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3263566-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | H. Lundbeck A/S (DK) | 2018-01-03 | — | — | EP | claimed |
| US-9656975-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2017-05-23 | — | — | US | claimed |
| US-20150057289-A1 | BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2015-02-26 | — | — | US | claimed |
| US-8921370-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-12-30 | — | — | US | claimed |
| EP-3263566-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | H. Lundbeck A/S (DK) | 2018-01-03 | — | — | EP | disclosed |
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | H. LUNDBECK A/S (DK) | 2017-08-03 | — | — | US | disclosed |
| EP-2654422-B1 | Bicyclo[3.2.1]octyl amide derivatives as allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5 or mGluR5) for the treatment of central nervous system (CNS) disorders | H LUNDBECK AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| US-9656975-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-20150057289-A1 | BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2015-02-26 | — | — | US | disclosed |
| US-8921370-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-12-30 | — | — | US | disclosed |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | SLC10A1, CLIC1, ABCB11 | NPSR1 1072/4885FPR2 2633/4885GRM5 3148/4885 |
| US-20150057289-A1 | BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME | SLC10A1, CLIC1, ABCB11 | NPSR1 1085/4885FPR2 2583/4885GRM5 3192/4885 |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | SLC10A1, CLIC1, ABCB11 | NPSR1 1072/4885FPR2 2633/4885GRM5 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.